---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-028529"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:32:28.057825+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbCellera receives Health Canada authorization for Phase 1 trial of ABCL575 for atopic dermatitis

## Summary
- Health Canada issued No Objection Letter authorizing Clinical Trial Application for ABCL575, an anti-OX40L antibody.
- ABCL575 is an Fc-silenced, half-life extended investigational antibody for moderate-to-severe atopic dermatitis.
- Phase 1 trial anticipated to start in Q3 2025, evaluating safety and pharmacokinetics in healthy participants.

## SEC filing metadata
- accession: 0001628280-25-028529
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000162828025028529/0001628280-25-028529-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000162828025028529/abcl-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-028529
- JSON: https://secwatch.observer/filing/0001628280-25-028529.json
- Plain text: https://secwatch.observer/filing/0001628280-25-028529.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.